Group Insurance Commission to require Vida Health program for GLP‑1 prescriptions, projects $15M in FY26 savings

VALERIE SULLIVAN, chair of the Group Insurance Commission, opened the October meeting with the commission’s plan to reduce a budget shortfall by tightening access to GLP‑1 weight‑loss drugs and by expanding CVS’s clinical pharmacy review.

GIC staff said Vida Health will become the sole prescriber for GLP‑1 medications used for obesity for GIC members starting Jan. 1, 2026, and that members currently on GLP‑1s will have a 90‑day transition to enroll in Vida. "This partnership will deliver annualized savings of $30,000,000 so the applying that to the second 6 months of this plan year we anticipate a $15,000,000 savings to us," said Matt Vino, a GIC staff presenter. Under the contract, Vida must meet operational, clinical and financial performance guarantees, and portions of its administrative fee are at risk if benchmarks are not met.

Why it matters: GIC staff said prescription spending on GLP‑1s has been a major driver of recent deficits. Staff told commissioners that roughly a quarter of a prior fiscal deficiency was attributable to growth in GLP‑1 use, and that the agency began the fiscal year with a noted budget deficiency the commission must close. Commissioners and staff framed the Vida requirement as a way to preserve access for members judged clinically…